Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.60 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1593475 | 0.98 | SIGMAR1 (0.62) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| SCHEMBL11203747 | 0.94 | SIGMAR1 (0.68) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| SCHEMBL11872505 | 0.92 | SIGMAR1 (0.71) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| SCHEMBL2001215 | 0.88 | CARM1 (0.64) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| SCHEMBL1088446 | 0.87 | SIGMAR1 (0.74) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| Hydrochloric Acid SCHEMBL394643 | 0.86 | CARM1 (0.62) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| Hydrochloric Acid SCHEMBL11109064 | 0.86 | CARM1 (0.62) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| SCHEMBL29733117 | 0.85 | SIGMAR1 (0.85) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| SCHEMBL7225346 | 0.85 | SIGMAR1 (0.85) | SIGMAR1CARM1PRMT6PRMT8LMNA | |
| Hydrochloric Acid SCHEMBL1087168 | 0.85 | SIGMAR1 (0.71) | SIGMAR1CARM1PRMT6PRMT8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099462-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | TRINSEO EUROPE GMBH (CH) | 2023-06-08 | — | — | WO | disclosed |
| EP-4186911-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | Trinseo Europe GmbH (CH) | 2023-05-31 | — | — | EP | disclosed |
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | disclosed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | disclosed |
| CN-106795100-B | Compound, pharmaceutical composition and its purposes in treatment neurodegenerative disease | 里尔大学 | 2019-11-19 | — | — | CN | disclosed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | disclosed |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-01-15 | — | — | US | disclosed |
| CN-106795100-A | Compound, pharmaceutical composition and its purposes in nerve degenerative diseases are treated | 法国里尔第二大学 | 2017-05-31 | — | — | CN | disclosed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
| US-4751223-A | Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0268793-A1 | Aminoalkyl tetracyclic benzodiazepines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-06-01 | — | — | EP | disclosed |
| US-4728652-A | VASODILATORS | E. R. SQUIBB & SONS, INC. (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0236902-A1 | 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-substituted-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters | E.R. Squibb & Sons, Inc. (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4684655-A | 1,2,3,4-tetrahydro-6-substituted-4-aryl-3-substituted-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and use thereof to lower blood pressure | E. R. SQUIBB & SONS, INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0202654-A2 | 5-Carboxy-1,4-dihydropyrimidine derivatives | E.R. Squibb & Sons, Inc. (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4405623-A | HYPOTENSIVE AGENTS, VASODILATORS | MASAYUKI ISHIKAWA (JP) | 1983-09-20 | — | — | US | disclosed |
| EP-0040793-A1 | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof | Ishikawa, Masayuki (JP) | 1981-12-02 | — | — | EP | disclosed |
| US-4232027-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-11-04 | — | — | US | disclosed |
| US-4021557-A | BRONCHOSPASMOLYTICS | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885CARM1 4151/4885PRMT6 4271/4885 |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885CARM1 4151/4885PRMT6 4271/4885 |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885CARM1 4151/4885PRMT6 4271/4885 |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885CARM1 4151/4885PRMT6 4271/4885 |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885CARM1 4151/4885PRMT6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.